XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury
Noncontrolling Interests
Opening retained earnings adjustments: adoption of new accounting standards
Opening retained earnings adjustments: adoption of new accounting standards
Retained Earnings
Adjusted balance
Adjusted balance
Common Stock
Adjusted balance
Additional Paid-in Capital
Adjusted balance
Retained Earnings
Adjusted balance
Accumulated Other Comprehensive Loss
Adjusted balance
Treasury
Adjusted balance
Noncontrolling Interests
Beginning balance, common stock (in shares) at Mar. 31, 2020   272                 272          
Beginning balance, treasury common stock (shares) at Mar. 31, 2020           (110)                 (110)  
Beginning balance at Mar. 31, 2020 $ 5,309 $ 2 $ 6,663 $ 13,022 $ (1,703) $ (12,892) $ 217 $ (13) $ (13) $ 5,296 $ 2 $ 6,663 $ 13,009 $ (1,703) $ (12,892) $ 217
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of shares under employee plans, net of forfeitures (in shares)   1                            
Issuance of shares under employee plans, net of forfeitures 64   92     $ (28)                    
Share-based compensation 151   151                          
Repurchase of common stock (in shares)           (5)                    
Repurchase of common stock (750)         $ (750)                    
Net income (loss) (4,383)     (4,539)     156                  
Other comprehensive income (loss) 223       223                      
Cash dividends declared (270)     (270)                        
Payments to noncontrolling interests (177)           (177)                  
Exercise of put right by noncontrolling shareholders of McKesson Europe AG 3   3                          
Other 18   16 2                        
Ending balance common stock (in shares) at Mar. 31, 2021   273                            
Ending balance, treasury common stock (shares) at Mar. 31, 2021           (115)                    
Ending balance at Mar. 31, 2021 175 $ 2 6,925 8,202 (1,480) $ (13,670) 196                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of shares under employee plans, net of forfeitures (in shares)   2                            
Issuance of shares under employee plans, net of forfeitures 149   220     $ (71)                    
Share-based compensation 154   154                          
Repurchase of common stock (in shares)           (15)                    
Repurchase of common stock (3,508)   (204)     $ (3,304)                    
Net income (loss) 1,279     1,114     165                  
Other comprehensive income (loss) 112       116   (4)                  
Cash dividends declared (279)     (279)                        
Payments to noncontrolling interests (155)           (155)                  
Exercise of put right by noncontrolling shareholders of McKesson Europe AG 8   178   (170)                      
Reclassification of McKesson Europe AG redeemable noncontrolling interests 287           287                  
Reclassification of recurring compensation to other accrued liabilities (7)           (7)                  
Other (7)   2 (7)     (2)                  
Ending balance common stock (in shares) at Mar. 31, 2022   275                            
Ending balance, treasury common stock (shares) at Mar. 31, 2022           (130)                    
Ending balance at Mar. 31, 2022 (1,792) $ 2 7,275 9,030 (1,534) $ (17,045) 480                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of shares under employee plans, net of forfeitures (in shares)   2                            
Issuance of shares under employee plans, net of forfeitures 4 $ 1 163     $ (160)                    
Share-based compensation 161   161                          
Repurchase of common stock (in shares)           (11)                    
Repurchase of common stock (3,665)   127     $ (3,792)                    
Net income (loss) 3,722     3,560     162                  
Other comprehensive income (loss) 673       629   44                  
Cash dividends declared (296)     (296)                        
Payments to noncontrolling interests (150)           (150)                  
Reclassification of recurring compensation to other accrued liabilities (5)           (5)                  
Formation of SCRI Oncology, LLC 247   22       225                  
Derecognition of noncontrolling interests in McKesson Europe AG (382)           (382)                  
Other (7)   (1) 1     (7)                  
Ending balance common stock (in shares) at Mar. 31, 2023   277                            
Ending balance, treasury common stock (shares) at Mar. 31, 2023           (141)                    
Ending balance at Mar. 31, 2023 $ (1,490) $ 3 $ 7,747 $ 12,295 $ (905) $ (20,997) $ 367